Effects of Two Aquatic Training Models in Physiological Parameters of Elderly Dyslipidemic Women.
9. September 2016 aktualisiert von: Hospital de Clinicas de Porto Alegre
Effects of Two Aquatic Training Models in Physiological Parameters of Elderly Dyslipidemic Women: a Randomized Controlled Clinical Trial.
This study aims to compare the effects of two water-based training models in physiological parameters of dyslipidemic elderly women.
Thus, a randomized controlled clinical trial will be conducted in parallel with the participation of 45 dyslipidemic elderly women.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The women will be randomly divided into three groups: water aerobics training (WA), resistance aquatic training (WR) and the third is the control group (who will perform relaxation sessions under water). The three groups will attend classes during 10 weeks, with two weekly sessions of 45 minutes each. The WA and WR groups will use the same four exercises in their training.
The WA group will be trained using the interval method, performing six blocks of five minutes each one, alternating four minutes at intensities corresponding to 90 to 100% of the heart rate corresponding to the second ventilatory threshold (HRVT2) and one minute at intensities between 80 and 90% HRVT2.
The WR group will perform four to eight sets of 20 to 10 seconds along the macrocycle, always at maximal speed execution of the exercises.
Will be measured, before and after the period of 10 weeks of intervention, biochemical, cardiorespiratory, neuromuscular and hemodynamic variables, parameters of quality of life and depressive symptoms in addition to the cardiovascular risk score of the participants of the three groups.
Data will be described by means values and lower and upper limits, with a 95% confidence interval. Comparisons between and within groups were performed using the method of generalized estimates of equations (GEE), with Bonferroni post hoc, adopting a 0.05 significance level.
Studientyp
Interventionell
Einschreibung (Tatsächlich)
45
Phase
- Unzutreffend
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
60 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Weiblich
Beschreibung
Inclusion Criteria:
- being female, aged between 60 and 75, sedentary (not practicing any kind of regular, supervised physical activity in the last three months), have any type of dyslipidemia.
Exclusion Criteria:
- women who are smokers, suffering from cardiovascular disease with associated complications and those with orthopedic diseases that prevented the practice of systematic physical exercise, users of hormone therapy drugs and lipid-lowering medications.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: WA (Water Aerobics Training)
Water aerobics training.
|
The WA group will be trained adopting the interval method, performing six blocks of five minutes each one, alternating four minutes at intensities corresponding to 90 to 100% of the heart rate corresponding to the second ventilatory threshold (HRVT2) and one minute at intensities between 80 and 90% HRVT2.
Andere Namen:
|
|
Experimental: WR (Water Resistance Training)
Resistance aquatic training.
|
The WR group will perform four to eight sets of 20 to 10 seconds along the macrocycle, always at maximal speed execution of the exercises.
Andere Namen:
|
|
Aktiver Komparator: CG (Control Group)
Control Group.
|
The control group will perform relaxation classes, including meditation, balance exercises, coordination exercises.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Total Cholesterol (TC) Change
Zeitfenster: Change from baseline total cholesterol at 10 weeks
|
This variable will be measured through blood collection after 12 hours fasting.
The analysis will be performed through the enzymatic method using kits Siemens, in automated equipment Advia 1800.
|
Change from baseline total cholesterol at 10 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Triglycerides (TG) Change
Zeitfenster: Change from baseline triglycerides at 10 weeks
|
This variable will be measured through blood collection after 12 hours fasting.
The analysis will be performed through the enzymatic method using kits Siemens, in automated equipment Advia 1800.
|
Change from baseline triglycerides at 10 weeks
|
|
High Density Lipoprotein (HDL) Change
Zeitfenster: Change from baseline HDL at 10 weeks
|
This variable will be measured through blood collection after 12 hours fasting.
The analysis will be performed through the enzymatic method using kits Siemens, in automated equipment Advia 1800.
|
Change from baseline HDL at 10 weeks
|
|
C-Reactive Protein (CRP) Change
Zeitfenster: Change from baseline C-reactive protein at 10 weeks
|
This variable will be measured through blood collection after 12 hours fasting.
The analysis will be performed through the turbidimetric method in Cobas Mira Plus equipment, with the Biotechnical Kit for ultrasensitive C-reactive protein.
|
Change from baseline C-reactive protein at 10 weeks
|
|
Low Density Lipoprotein (LDL) Change
Zeitfenster: Change from baseline LDL at 10 weeks
|
This variable will be estimated by Friedewald equation.
|
Change from baseline LDL at 10 weeks
|
|
Total Cholesterol/High Density Lipoprotein Ratio (TC/HDL ratio) Change
Zeitfenster: Change from baseline TC/HDL at 10 weeks
|
This variable will be estimated by the simple division of variables.
|
Change from baseline TC/HDL at 10 weeks
|
|
Peak Oxygen Consumption (VO2peak) Change
Zeitfenster: Change from baseline VO2peak at 10 weeks
|
This outcome will be measure through maximal progressive treadmill test, using the portable gas analyser VO2000 equipment.
|
Change from baseline VO2peak at 10 weeks
|
|
Oxygen Consumption at anaerobic threshold (VO2VT2) Change
Zeitfenster: Change from baseline VO2VT2 at 10 weeks
|
This outcome will be measure through maximal progressive treadmill test, using the portable gas analyser VO2000 equipment.
|
Change from baseline VO2VT2 at 10 weeks
|
|
Heart Rate at anaerobic threshold (HRVT2) Change
Zeitfenster: Change from baseline HRVT2 at 10 weeks
|
This outcome will be measure through maximal progressive treadmill test, using a heart rate monitor (POLAR, FT1).
|
Change from baseline HRVT2 at 10 weeks
|
|
Rest Heart Rate (HRrest) Change
Zeitfenster: Change from baseline HRrest at 10 weeks
|
This outcome will be measure using a heart rate monitor (POLAR, FT1).
The participants will remain seated in a quiet and controlled temperature room during 15 minutes prior to measurement of the heart rate.
|
Change from baseline HRrest at 10 weeks
|
|
Lipoprotein Lipase (LPL) Change
Zeitfenster: Change from baseline LPL at 10 weeks
|
This variable will be measured through blood collection after 12 hours fasting.
The analysis will be performed using the LPL ELISA kit (Cell Biolabs).
The results will be read in a microplate reader (ELISA).
|
Change from baseline LPL at 10 weeks
|
|
Maximal dynamic muscle strength of knees extensors (MSKE) Change
Zeitfenster: Change from baseline MSKE at 10 weeks
|
This outcome will be measured through the one-repetition maximal test (1RM).
|
Change from baseline MSKE at 10 weeks
|
|
Maximal dynamic muscle strength of knees flexors (MSKF) Change
Zeitfenster: Change from baseline MSKF at 10 weeks
|
This outcome will be measured through the one-repetition maximal test (1RM).
|
Change from baseline MSKF at 10 weeks
|
|
Maximal dynamic muscle strength of horizontal shoulder flexors (MSHSF) Change
Zeitfenster: Change from baseline MSHSF at 10 weeks
|
This outcome will be measured through the one-repetition maximal test (1RM).
|
Change from baseline MSHSF at 10 weeks
|
|
Rest Cardiac Output (COrest) Change
Zeitfenster: Change from baseline COrest at 10 weeks
|
This outcome will be measured through Impedance Cardiography (Physioflow Lab-1 equipment).
The participants will remain seated in a quiet and controlled temperature room during 15 minutes prior to measurement of the cardiac output.
|
Change from baseline COrest at 10 weeks
|
|
Rest Stroke Volume (SVrest) Change
Zeitfenster: Change from baseline SVrest at 10 weeks
|
This outcome will be measured through Impedance Cardiography (Physioflow Lab-1 equipment).
The participants will remain seated in a quiet and controlled temperature room during 15 minutes prior to measurement of the stroke volume.
|
Change from baseline SVrest at 10 weeks
|
|
Peak Cardiac Output (COpeak) Change
Zeitfenster: Change from baseline COpeak at 10 weeks
|
This outcome will be measured through Impedance Cardiography (Physioflow Lab-1 equipment), during a maximal progressive treadmill test.
|
Change from baseline COpeak at 10 weeks
|
|
Peak Stroke Volume (SVpeak) Change
Zeitfenster: Change from baseline SVpeak at 10 weeks
|
This outcome will be measured through Impedance Cardiography (Physioflow Lab-1 equipment), during a maximal progressive treadmill test.
|
Change from baseline SVpeak at 10 weeks
|
|
Rest Arterial Systolic Blood Pressure (SBPrest) Change
Zeitfenster: Change from baseline SBPrest at 10 weeks
|
This outcome will be measured through blood pressure ambulatory monitor (Meditech, ABPM-04).
The participants will remain seated in a quiet and controlled temperature room during 15 minutes prior to measurement of the arterial systolic blood pressure.
|
Change from baseline SBPrest at 10 weeks
|
|
Rest Arterial Diastolic Blood Pressure (DBPrest) Change
Zeitfenster: Change from baseline DBPrest at 10 weeks
|
This outcome will be measured through blood pressure ambulatory monitor (Meditech, ABPM-04).
The participants will remain seated in a quiet and controlled temperature room during 15 minutes prior to measurement of the arterial diastolic blood pressure.
|
Change from baseline DBPrest at 10 weeks
|
|
Cardiovascular Risk Score (CRS) Change
Zeitfenster: Change from baseline cardiovascular risk score at 10 weeks
|
The Reynolds Risk Score Instrument will be used to estimate the cardiovascular risk.
|
Change from baseline cardiovascular risk score at 10 weeks
|
|
Quality of Life Change
Zeitfenster: Change from baseline quality of life at 10 weeks
|
The quality of life will be estimated using the Whoqol-Bref instrument.
|
Change from baseline quality of life at 10 weeks
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Ermittler
- Hauptermittler: Ricardo Stein, Hospital de Clinicas de Porto Alegre
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. Dezember 2015
Primärer Abschluss (Tatsächlich)
1. März 2016
Studienabschluss (Tatsächlich)
1. Mai 2016
Studienanmeldedaten
Zuerst eingereicht
6. September 2016
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
9. September 2016
Zuerst gepostet (Schätzen)
14. September 2016
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
14. September 2016
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
9. September 2016
Zuletzt verifiziert
1. September 2016
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 14-0547
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
UNENTSCHIEDEN
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .